StageZero Life Sciences Ltd Cash Flow Conversion Efficiency
StageZero Life Sciences Ltd cash flow conversion efficiency. Based on the latest financial reports, StageZero Life Sciences Ltd (SZLS) has a cash flow conversion efficiency ratio of 0.013x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-145.57K ≈ $-105.30K USD) by net assets (CA$-11.13 Million ≈ $-8.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of StageZero Life Sciences Ltd (1998–2022)
Cash flow conversion efficiency of StageZero Life Sciences Ltd from 1998 to 2022. This chart illustrates how StageZero Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View StageZero Life Sciences Ltd (SZLS) stock price for real-time trading data and today's change.
StageZero Life Sciences Ltd Cash Flow Conversion Ratio Explained
StageZero Life Sciences Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
StageZero Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of StageZero Life Sciences Ltd ranked by their cash flow conversion efficiency. Also see SZLS market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akshar Spintex Limited
NSE:AKSHAR
|
0.025x |
|
Pasukhas Group Bhd
KLSE:0177
|
-0.018x |
|
South HARZ Potash Ltd
AU:SHP
|
-0.877x |
|
Social Housing REIT plc
LSE:SOHO
|
0.034x |
|
Pensionbee Group PLC
LSE:PBEE
|
-0.027x |
|
Capricorn Energy PLC
LSE:CNE
|
0.335x |
|
Diriteks Dirilis Tekstil Sanayi ve Ticaret AS
IS:DIRIT
|
-0.030x |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
-0.026x |
Annual Cash Flow Conversion Efficiency for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual cash flow conversion efficiency of StageZero Life Sciences Ltd from 1998 to 2022. Review StageZero Life Sciences Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | CA$-7.50 Million ≈ $-5.43 Million |
CA$-3.53 Million ≈ $-2.55 Million |
0.470x | +114.50% |
| 2021-12-31 | CA$2.76 Million ≈ $2.00 Million |
CA$-8.95 Million ≈ $-6.48 Million |
-3.242x | -230.51% |
| 2020-12-31 | CA$-1.23 Million ≈ $-892.28K |
CA$-3.06 Million ≈ $-2.22 Million |
2.484x | +143.05% |
| 2019-12-31 | CA$-4.49 Million ≈ $-3.25 Million |
CA$-4.59 Million ≈ $-3.32 Million |
1.022x | +50.23% |
| 2018-12-31 | CA$-4.84 Million ≈ $-3.50 Million |
CA$-3.29 Million ≈ $-2.38 Million |
0.680x | -46.33% |
| 2017-12-31 | CA$-3.02 Million ≈ $-2.18 Million |
CA$-3.82 Million ≈ $-2.77 Million |
1.268x | +62.76% |
| 2016-12-31 | CA$-4.73 Million ≈ $-3.42 Million |
CA$-3.68 Million ≈ $-2.66 Million |
0.779x | -20.01% |
| 2015-12-31 | CA$-1.77 Million ≈ $-1.28 Million |
CA$-1.73 Million ≈ $-1.25 Million |
0.974x | +236.66% |
| 2014-12-31 | CA$2.15 Million ≈ $1.56 Million |
CA$-1.54 Million ≈ $-1.11 Million |
-0.713x | +71.36% |
| 2013-12-31 | CA$1.74 Million ≈ $1.26 Million |
CA$-4.34 Million ≈ $-3.14 Million |
-2.488x | -210.51% |
| 2012-12-31 | CA$5.07 Million ≈ $3.67 Million |
CA$-4.06 Million ≈ $-2.94 Million |
-0.801x | -109.11% |
| 2011-12-31 | CA$-321.56K ≈ $-232.61K |
CA$-2.83 Million ≈ $-2.05 Million |
8.800x | +131.32% |
| 2010-12-31 | CA$87.69K ≈ $63.43K |
CA$-2.46 Million ≈ $-1.78 Million |
-28.100x | -1417.74% |
| 2009-12-31 | CA$2.49 Million ≈ $1.80 Million |
CA$-4.61 Million ≈ $-3.34 Million |
-1.851x | +57.36% |
| 2008-12-31 | CA$1.73 Million ≈ $1.25 Million |
CA$-7.51 Million ≈ $-5.43 Million |
-4.342x | -622.04% |
| 2007-12-31 | CA$13.81 Million ≈ $9.99 Million |
CA$-8.31 Million ≈ $-6.01 Million |
-0.601x | -88.69% |
| 2006-12-31 | CA$19.54 Million ≈ $14.13 Million |
CA$-6.23 Million ≈ $-4.51 Million |
-0.319x | -80.16% |
| 2005-12-31 | CA$5.93 Million ≈ $4.29 Million |
CA$-1.05 Million ≈ $-758.95K |
-0.177x | +45.23% |
| 2004-12-31 | CA$7.69 Million ≈ $5.56 Million |
CA$-2.48 Million ≈ $-1.80 Million |
-0.323x | -294.68% |
| 2003-12-31 | CA$5.74 Million ≈ $4.15 Million |
CA$-469.80K ≈ $-339.85K |
-0.082x | +80.16% |
| 2002-12-31 | CA$1.71 Million ≈ $1.24 Million |
CA$-707.49K ≈ $-511.78K |
-0.413x | +9.50% |
| 2001-12-31 | CA$2.29 Million ≈ $1.66 Million |
CA$-1.04 Million ≈ $-755.27K |
-0.456x | +43.12% |
| 2000-12-31 | CA$2.32 Million ≈ $1.68 Million |
CA$-1.86 Million ≈ $-1.34 Million |
-0.801x | +6.73% |
| 1999-12-31 | CA$34.76K ≈ $25.15K |
CA$-29.87K ≈ $-21.61K |
-0.859x | -2739.35% |
| 1998-12-31 | CA$165.36K ≈ $119.62K |
CA$-5.00K ≈ $-3.62K |
-0.030x | -- |
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more